Inclisiran is a
small interfering RNA that acts as an
inhibitor of an enzyme that degrades LDL receptors and thereby increases LDL levels in the blood. Since Inclisiran inhibits the degradation of receptors, it results in an increased number of receptors, and therefore LDL is removed from the blood. More specifically, Inclisiran inhibits
translation of the protein termed proprotein convertase subtilisin/kexin type 9 (
PCSK9). Small interfering RNA molecules (siRNAs) are designed to intervene in the pathway of RNA interference (RNAi), a naturally operating mechanism, wherein they bind to a complex within the cell termed the RNA-induced silencing complex (RISC); after binding, the RISC structure in the siRNA-RISC complex is altered, allowing it to cleave specific messenger RNA molecules (mRNAs). The siRNA-RISC complex is
catalytic, and thus can cleave multiple copies of the mRNA that it targets; cleaved mRNAs are not
translated into proteins, and thus since less of the target protein is made, the resulting concentration of the protein targeted by the siRNA design is decreased. The proprotein convertase, PCSK9, is a liver-produced and secreted serine protease whose binding and action on LDL receptor protein result in their increased lysosomal degradation in hepatocytes. A consequence of this is an increase in the level of circulating LDL cholesterol in the bloodstream (and conversely, inhibition of which results in a decrease in this level). Studies of PCSK9 genetics supported the conclusion that decreases in circulating LDL cholesterol accomplished in this way would result in "diminished cardiovascular risk... with no apparent negative health consequences". Also, long term administration of antibodies with short
in vivo half-lives, 1-2 times a month, reduced circulating PCSK9 and LDL cholesterol levels, with the result of a "lower incidence of cardiovascular events than placebo". Together, these results contributed to the validation of PCSK9-targeting siRNAs for development as a new therapeutic for use in LDL cholesterol–lowering therapy; specifically, small interfering RNA (siRNA) molecules of appropriate sequence and structure targeting mRNA encoding PCSK9 were sought and discovered as a means of decreasing PCSK9 levels, and the development of a clinical candidate ensued thereafter. == History ==